AngioDynamics (ANGO) Downgraded by BidaskClub

BidaskClub downgraded shares of AngioDynamics (NASDAQ:ANGO) from a hold rating to a sell rating in a research note released on Thursday.

A number of other analysts have also recently weighed in on ANGO. Zacks Investment Research cut shares of AngioDynamics from a buy rating to a hold rating in a research report on Friday, January 26th. Craig Hallum cut shares of AngioDynamics from a buy rating to a hold rating in a research report on Friday, January 5th. Finally, TheStreet cut shares of AngioDynamics from a b- rating to a c rating in a research report on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company. The stock has an average rating of Hold and an average price target of $18.60.

Shares of AngioDynamics (ANGO) opened at $16.54 on Thursday. The company has a current ratio of 2.56, a quick ratio of 1.65 and a debt-to-equity ratio of 0.17. AngioDynamics has a 12-month low of $14.80 and a 12-month high of $18.85. The firm has a market cap of $607.76, a price-to-earnings ratio of 25.06, a P/E/G ratio of 1.53 and a beta of 0.98.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Thursday, January 4th. The medical instruments supplier reported $0.16 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.16. AngioDynamics had a negative net margin of 2.27% and a positive return on equity of 4.63%. The firm had revenue of $86.70 million during the quarter, compared to analysts’ expectations of $88.15 million. During the same period in the prior year, the company earned $0.19 EPS. The firm’s revenue was down 2.6% on a year-over-year basis. analysts anticipate that AngioDynamics will post 0.72 earnings per share for the current year.

A number of large investors have recently bought and sold shares of ANGO. Alliancebernstein L.P. boosted its position in AngioDynamics by 53.6% in the 2nd quarter. Alliancebernstein L.P. now owns 49,290 shares of the medical instruments supplier’s stock valued at $799,000 after buying an additional 17,200 shares during the last quarter. Teachers Advisors LLC boosted its position in AngioDynamics by 9.0% in the 2nd quarter. Teachers Advisors LLC now owns 84,021 shares of the medical instruments supplier’s stock valued at $1,362,000 after buying an additional 6,928 shares during the last quarter. TIAA CREF Investment Management LLC boosted its position in AngioDynamics by 23.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 289,160 shares of the medical instruments supplier’s stock valued at $4,687,000 after buying an additional 55,444 shares during the last quarter. Thrivent Financial For Lutherans boosted its position in AngioDynamics by 13.4% in the 2nd quarter. Thrivent Financial For Lutherans now owns 20,610 shares of the medical instruments supplier’s stock valued at $334,000 after buying an additional 2,430 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its position in AngioDynamics by 6.1% in the 2nd quarter. New York State Common Retirement Fund now owns 43,720 shares of the medical instruments supplier’s stock valued at $709,000 after buying an additional 2,519 shares during the last quarter. 94.55% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/18/angiodynamics-ango-downgraded-by-bidaskclub.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply